19 12 minutes ago Biotech Stocks Healthcare Stocks Small Caps Stocks Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review Cynata Therapeutics (ASX:CYP) Phase 3 knee osteoarthritis trial missed both endpoints, triggering a review of the entire Cymerus platform. ByCharlie Youlden